Celgene's new triple-combo FDA nods shift Revlimid, Pomalyst into higher gear
admin 30th July 2019 Uncategorised 0Celgene has provided Bristol-Myers Squibb investors an updated look at the business they’re buying—and not getting. Myeloma drugs Revlimid and Pomalyst and to-be-sold Otezla all delivered double-digit growth in the second quarter.
More: Celgene's new triple-combo FDA nods shift Revlimid, Pomalyst into higher gear
Source: fierce